Search Within

Jose T Baselga

Formats
  1. Meeting Abstract (241)
  2. Journal Article (233)
  3. Conference Paper (4)
  4. Research Letter (3)
  5. Book Section (2)
  6. Review (1)
Groups
  1. Department of Medicine (197)
  2. Solid Tumor Oncology Division (192)
  3. Breast Medicine Service (149)
  4. GSK Faculty (128)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (108)
  6. Human Oncology and Pathogenesis Program (97)

More Groups

People
  1. David Hyman (68)
  2. Maurizio Scaltriti (63)
  3. Clifford Hudis (57)
  4. Michael Berger (56)
  5. Larry Norton (51)
  6. Sarat Chandarlapaty (48)

More People

Years
  1. 2021 (5)
  2. 2020 (11)
  3. 2019 (25)
  4. 2018 (58)
  5. 2017 (68)
  6. 2016 (67)

More Years

Publications
  1. Cancer Research (109)
  2. Journal of Clinical Oncology (92)
  3. Annals of Oncology (29)
  4. Clinical Cancer Research (29)
  5. European Journal of Cancer (25)
  6. Cancer Discovery (13)

More Publications

Publishers
  1. American Association for Cancer Research (163)
  2. American Society of Clinical Oncology (97)
  3. Oxford University Press (41)
  4. Elsevier Inc. (39)
  5. Nature Publishing Group (30)
  6. Springer (16)

More Publishers

Results (484)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2
    Meeting Abstract

    Rugo, H. S.; Hortobagyi, G. N.; Piccart-Gebhart, M. J.; Burris, H. A.; Campone, M.; Noguchi, S.; Perez, A. T.; Deleu, I.; Shtivelband, M.; Provencher, L.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2
    Meeting Abstract

    Hortobagyi, G. N.; Piccart-Gebhart, M. J.; Rugo, H. S.; Burris, H. A.; Campone, M.; Noguchi, S.; Perez, A. T.; Deleu, I.; Shtivelband, M.; Provencher, L.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS signaling
    Meeting Abstract

    Will, M.; Toy, W.; Yao, Z.; Poulikakos, P.; Rodrik-Outmezguine, V. ; Schneider, C.; Paul, J.; Baselga, J.; Liu, N.; Rosen, N.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • p90RSK mediates resistance to PI3K-pathway inhibitors in breast cancer
    Meeting Abstract

    Serra, V.; Eichhorn, P. J. A.; Garcia-Garcia, C.; Ibrahim, Y.; Prudkin, L.; Rodriguez, O.; Marlow, S.; Prat, A.; Hahn, W. C.; Baselga, J.
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Combined blockade of PI3K/AKT and EGFR/HER3 enhances antitumor activity in triple negative breast cancer
    Meeting Abstract

    Scaltriti, M.; Tao, J.; Juric, D.; Auricchio, N.; Castel, P.; Morse, N.; Kim, P.; Singh, S.; Hazra, S.; Hembrough, T.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor
    Meeting Abstract

    Rodon, J.; Juric, D.; Gonzalez-Angulo, A. M.; Bendell, J.; Berlin, J.; Bootle, D.; Gravelin, K.; Huang, A.; Derti, A.; Lehár, J.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Sensitivity to combined MEK and mTORC1/2 inhibition in colorectal cancer is dictated by p53 mutational status
    Meeting Abstract

    Garcia-Garcia, C.; Rivas, M. A.; Ibrahim, Y. H.; Calvo, M. T.; Grueso, J.; Antón, P.; Aura, C.; Jessen, K.; Palmer, H.; Tabernero, J.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Translation of preclinical predictive sensitivity of Ewing sarcoma to PARP inhibition: Phase II study of olaparib in adult patients with recurrent/metastatic Ewing sarcoma following failure of prior chemotherapy
    Meeting Abstract

    Choy, E.; Butrynski, J.; Harmon, D.; Morgan, J.; George, S.; Wagner, A.; D'adamo, D.; Cote, G.; Rubinstein, Y.; Benes, C.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • A phase II randomized placebo-controlled study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, plus paclitaxel (P) vs P alone in patients (pts) with low HER2-expressing advanced breast cancer (BC) (THYME)
    Meeting Abstract

    Baselga, J.; Hegg, R.; Losada, M. V.; Vidaurre, T.; Lluch, A.; Petrakova, K.; Mann, H.; Ghiorghiu, S.; Stuart, M.; Landers, D.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Evaluation of tolerability and anti-tumor activity of GDC-0032, a PI3K inhibitor with enhanced activity against PIK3CA mutant tumors, administered-to patients with advanced solid tumors
    Meeting Abstract

    Juric, D.; Infante, J. R.; Krop, I. E.; Kurkjian, C.; Patel, M. R.; Graham, R. A.; Wilson, T. R.; Hsu, J. Y.; Baselga, J.; Von Hoff, D. D.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save